Maegim한국어

유바이오로직스

206650KOSDAQSector: Pharma & Biotech
₩7,620▲ 0.26%Market cap ₩280.1BAs of Jul 21, 2026 close · updated once daily
A
Grade A78.6 ptsTop 2% of 2,523 stocks
Financial strength
82.0
Growth momentum
85.4
Price attractiveness
69.9

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

82.0
How much debt does it carry relative to equity?
Debt-to-equity ratio
37.0%
✓ Above median · Top 33.5% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
328.5%
✓ Above median · Top 32.7% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
40.7%
✓ Above median · Top 2.3% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
23.5%
✓ Above median · Top 3.5% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original ↗

2

Growth momentum

85.4
How much did revenue grow in a year?
Revenue growth (YoY)
55.4%
✓ Above median · Top 13.9% in sector
Sector median 6.4%
Did core profits grow in a year?
Operating income change (YoY)
76.8%
✓ Above median · Top 15.4% in sector
Sector median 3.6%

Source filing: annual report (separate) — view original ↗

3

Price attractiveness

69.9
Is the price expensive relative to earnings?
P/E (price-to-earnings)
6.8x
✓ Above median · Top 6.7% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
1.60x
✗ Below median · Top 53.5% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15